Clinical trials: Relapsed/Refractory B-cell ALL
Lymphoblastic Leukemia, Acute
Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).
- Trial name
- NCT00995137
- Testing
- NK Cell Infusion
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
This phase I trial studies the best dose and side effects of flotetuzumab for the treatment of patients with blood cancers (hematological malignancies) that have spread to other places in the body (advanced) and have come back…
- Conditions
- Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT04681105
- Testing
- Acetaminophen, Dexamethasone, Diphenhydramine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Chronic Lymphocytic Leukemia
Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia
CLL is an incurable disease with conventional chemotherapy. In the absence of TP53 disruption, a chemoimmunotherapy (CIT) regimen is recommended as front-line and second-line treatment in those patients who attained a long…
- Trial name
- NCT03847727
- Testing
- BR as Maintenance
- Where
- Russia
- Volunteers
- 112 people
- Sponsor
- Pirogov Russian National Research Medical University
Relapsed B-Cell Non-Hodgkin Lymphoma
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
Open-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma.
- Trial name
- NCT07477366
- Testing
- CD19 t-haNK- IV Administration, N-803, rituximab
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
B-Cell Lymphoblastic Leukemia/Lymphoma
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD20 bispecific CAR-T cells in relapsed /…
- Trial name
- NCT06503094
- Testing
- CD19&CD20 bispecific CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for…
- Trial name
- NCT02077166
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 40 sites in United States, Belgium and 2 more
- Volunteers
- 138 people
- Sponsor
- Pharmacyclics LLC.
Leukemia
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00812669
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 7 sites in Ireland
- Volunteers
- 52 people
- Sponsor
- Cancer Trials Ireland
Relapsed/Refractory B-cell Lymphoma
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292 and lenalidomide combination therapy.
- Trial name
- CLEAR (NCT01766583)
- Testing
- CC-292 + lenalidomide
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- The Lymphoma Academic Research Organisation
Anemia, Fatigue
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
This pilot clinical trial studies the side effects and best dose of metformin hydrochloride and ritonavir in treating patients with multiple myeloma or chronic lymphocytic leukemia that has returned after a period of improvement…
- Conditions
- Anemia, Fatigue, Fever, Lymphadenopathy
- Trial name
- NCT02948283
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Pharmacological Study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This phase II trial studies how well alisertib with and without rituximab works in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01812005
- Testing
- alisertib, rituximab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Lymphoblastic Leukemia
Phase III B in Acute Lymphoblastic Leukemia
This is a single arm, open-label, multi-center, phase III B study to determine the safety and efficacy of CTL019 in pediatric/young adult patients with r/r B-cell Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT03123939
- Testing
- CTL019
- Where
- 11 sites in Austria, Belgium and 7 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This phase II trial is studying how well PXD101 works in treating patients with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00303953
- Testing
- belinostat
- Where
- 123 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia
- Trial name
- NCT04030195
- Testing
- PBCAR20A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Leukemia, Lymphocytic, Chronic
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding…
- Trial name
- NCT00076401
- Testing
- Motexafin gadolinium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pharmacyclics LLC.
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma
Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
This phase II trial compares the effect of mosunetuzumab alone to mosunetuzumab with zanubrutinib or polatuzumab vedotin in patients with marginal zone lymphoma that has come back after a period of improvement (relapsed) or that…
- Conditions
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT07638722
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 14 sites in United States
- Volunteers
- 138 people
- Sponsor
- SWOG Cancer Research Network
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is…
- Conditions
- Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04323657
- Testing
- TC-110 T Cells, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- TCR2 Therapeutics
Relapsed or Refractory B-cell Lymphomas
The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma
The present study is an exploratory study. Patients who meeting the enrollment conditions for relapsed or refractory B-cell lymphoma receive a single intravenous dose of CD20-CART cells.
- Trial name
- NCT03576807
- Testing
- CD20 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xin Wang
Leukemia, B-cell
γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse
Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- γδT (NCT04439721)
- Testing
- γδT Cell infusion agent
- Where
- China
- Volunteers
- 5 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
The primary objectives of this study are to evaluate safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of idelalisib; and to establish recommended phase 2 doses (RP2D) of idelalisib in combination with…
- Trial name
- NCT03349346
- Testing
- Idelalisib, Rituximab, Ifosfamide
- Where
- 7 sites in France, Italy and 2 more
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.